Compare AstraZeneca plc (AZN) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? AstraZeneca plc trades at $158.76 (market cap $248.14B), while Global X NASDAQ 100 Covered Call ETF trades at $18.17. The key difference: AstraZeneca plc pays a 2.01% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | QYLD | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $18.52 |
52-Week Low | $147.06 | $16.46 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
QYLD trades at $18.18, up 0.17% with a bullish technical signal from moving averages but bearish oscillators. The ETF maintains its covered call strategy, generating consistent monthly dividends, though financial ratios are unavailable. Recent news highlights both the appeal of its 11.67% yield and concerns about long-term underperformance versus the Nasdaq-100.
Outlook: High income potential in sideways markets, but capital appreciation is limited. Risks include erosion of NAV during bull markets and competition from lower-fee alternatives. Suitable for income-focused investors willing to sacrifice growth for yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
